Back

Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.

30 August 2024 (12:00 - 12:50)
Organised by: Logo
Congress Presentation Part of: Liver metabolism and heart disease Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Satoshi Kitahara

Kashiwa Kosei General Hospital, Kashiwa (Japan)

6 More presentations in this session

Presentation thumbnail
Serum lipid profiles and uptake of lipid-lowering therapy in patients with premature atherosclerotic cardiovascular disease (ASCVD) in comparison to older patients with ASCVD
Professor T. Tan (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibitors in HIV patients with dyslipidemia
Doctor S. Datla (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease
Doctor E. Aivalioti (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with nonalcoholic fatty liver disease.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The association of steatotic liver disease with recurrent ischemic events in patients with chronic coronary syndrome: a multicenter cohort study
Doctor G. Zeng (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Liver metabolism and heart disease

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic predictive value of circulating angiopoietin-like protein 3 in patients with chronic coronary syndrome
thumbnail
Congress Presentation
Apolipoprotein B and the regression of lipidic plaque in statin-treated type 2 DM patients with coronary artery disease: the pre-specified sub-analysis from the OPTIMAL randomized controlled trial
thumbnail
Congress Presentation
Lowering apolipoprotein C-III associates with regression of lipidic plaque materials in type 2 DM patients with coronary artery disease: the pre-specified analysis from the OPTIMAL trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources